Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

2013 ecancer highlights

Published: 11 Dec 2013

Views: 1688

Rating:

Save

Prof Gordon McVie - ecancer and European Institute of Oncology

Managing Editor Prof Gordon McVie talks through the most popular content from ecancer in 2013.

Categories:
Personalised medicine

Related Videos

New classification for identifying HR myeloma based on cytogenetic abnormalities

Dr Jill Corre - IUCT Oncopole, Toulouse, France

New classification for identifying HR myeloma based on cytogenetic abnormalities ( Dr Jill Corre - IUCT Oncopole, Toulouse, France )

Daratumumab, bortezomib/thalidomide/dexamethasone (D-VTd) and DARA maintenance...

Dr Jill Corre - IUCT Oncopole, Toulouse, France

Daratumumab, bortezomib/thalidomide/dexamethasone (D-VTd) and DARA maintenance shows benefit in transplant-eligible NDMM ( Dr Jill Corre - IUCT Oncopole, Toulouse, France )

Isatuximab plus lenalidomide and dexamethasone with bortezomib as a new...

Prof Xavier Leleu - CHU de Poitiers, Poitiers, France

Isatuximab plus lenalidomide and dexamethasone with bortezomib as a new standard of care for NDMM TI non-frail patients ( Prof Xavier Leleu - CHU de Poitiers, Poitiers, France )

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM

Dr Elias Mai - Heidelberg University, Heidelberg, Germany

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM ( Dr Elias Mai - Heidelberg University, Heidelberg, Germany )

Use of bispecifics and CAR T cells in South America

Dr Natalia Schütz - Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

Use of bispecifics and CAR T cells in South America ( Dr Natalia Schütz - Hospital Italiano de Buenos Aires, Buenos Aires, Argentina )

Revolutionising myeloma treatment through immune profiling

Dr Romanos Sklavenitis-Pistofidis - Dana-Farber Cancer Institute, Boston, USA

Revolutionising myeloma treatment through immune profiling ( Dr Romanos Sklavenitis-Pistofidis - Dana-Farber Cancer Institute, Boston, USA )

Treating relapsed multiple myeloma outside of use of T-cell redirected therapies

Prof Joy Ho - The University of Sydney, Sydney, Australia

Treating relapsed multiple myeloma outside of use of T-cell redirected therapies ( Prof Joy Ho - The University of Sydney, Sydney, Australia )

Guiding transplant decisions in multiple myeloma with MRD

Dr Susan Bal - University of Alabama at Birmingham, Birmingham, USA

Guiding transplant decisions in multiple myeloma with MRD ( Dr Susan Bal - University of Alabama at Birmingham, Birmingham, USA )

Revolutionising multiple myeloma treatment with CAR T-Cell therapies

Dr Susan Bal - University of Alabama at Birmingham, Birmingham, USA

Revolutionising multiple myeloma treatment with CAR T-Cell therapies ( Dr Susan Bal - University of Alabama at Birmingham, Birmingham, USA )

More from ecancer